Rice Hall James & Associates LLC cut its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 7.4% in the 1st quarter, Holdings Channel.com reports. The firm owned 887,126 shares of the biopharmaceutical company’s stock after selling 70,562 shares during the quarter. ACADIA Pharmaceuticals comprises 0.9% of Rice Hall James & Associates LLC’s holdings, […]
StockNews.com downgraded shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) from a buy rating to a hold rating in a research report report published on Wednesday. ACAD has been the topic of several other research reports. Bank of America raised their price target on shares of ACADIA Pharmaceuticals from $26.00 to $29.00 in a research […]
Crown Advisors Management Inc. purchased a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) in the 1st quarter, Holdings Channel reports. The fund purchased 30,000 shares of the biopharmaceutical company’s stock, valued at approximately $564,000. Several other hedge funds and other institutional investors have also recently made changes to their positions […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) – Research analysts at Leerink Partnrs reduced their Q3 2023 earnings per share estimates for shares of ACADIA Pharmaceuticals in a report released on Wednesday, August 2nd. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaceutical company will post earnings per share of ($0.41) for the quarter, […]
Oppenheimer reissued their market perform rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a research report report published on Thursday, Benzinga reports. They currently have a $25.00 price target on the biopharmaceutical company’s stock. Other analysts have also recently issued research reports about the stock. JMP Securities upped their price objective on […]